CEA CAR-T cells

BIOLOGICAL4 trials

Sponsors

Chongqing Precision Biotech Co., Ltd, Weijia Fang, MD

Conditions

Breast CancerCholangiocarcinomaColon CancerColorectal CancerEsophageal CancerEsophagus CancerGastric CancerLiver Cancer

Phase 1

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

WithdrawnNCT04348643

Chongqing Precision Biotech Co., LtdBreast Cancer, Colorectal Cancer, Gastric Cancer +4

Start: 2020-02-20End: 2024-04-30Updated: 2026-07-10

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

CompletedNCT05396300

Weijia Fang, MDColorectal Cancer, Gastric Cancer, Solid Cancers

Start: 2022-05-25End: 2026-06-30Updated: 2026-07-15

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

CompletedNCT05415475

Chongqing Precision Biotech Co., LtdColorectal Cancer, Esophageal Cancer, Metastatic Tumor +3

Start: 2021-09-10End: 2025-09-15Updated: 2026-07-09

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

RecruitingNCT06010862

Chongqing Precision Biotech Co., LtdBreast Cancer, Cholangiocarcinoma, Colon Cancer +4

Start: 2023-09-30End: 2026-09-30Target: 36Updated: 2023-11-08

Related Papers

Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.

Journal of Clinical Oncology2026-05-27

Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.

2026-02-27

Removal: “Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer”

Therapeutic Advances in Medical Oncology2024-10-014 citations

Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.

Journal of Clinical Oncology2024-06-0116 citations